ADC Therapeutics SA (NYSE: ADCT) — Company Overview, News & Financial Data
ADC Therapeutics develops antibody-drug conjugates for targeted cancer therapies.
ADC Therapeutics SA
ADC Therapeutics (NYSE:ADCT) specializes in the development of antibody-drug conjugates (ADCs) for treating various types of cancers. With a focus on leveraging its proprietary technology to develop highly potent and targeted cancer therapies, ADC Therapeutics aims to revolutionize cancer treatment. Their pipeline includes several projects in various stages of clinical development, designed to address the unmet needs of cancer patients across a broad range of hematologic and solid tumors. The company's primary objective is to advance its lead candidates through clinical trials toward regulatory approval, while also exploring potential new therapeutic applications for its technology platform. Through rigorous research and innovation, ADC Therapeutics is committed to improving outcomes for patients facing challenging cancer diagnoses.
Snapshot
Operations
Products and/or services of ADC Therapeutics SA
- ZYNLONTA (loncastuximab tesirine-lpyl), a CD19-directed antibody-drug conjugate for the treatment of relapsed or refractory diffuse large B-cell lymphoma.
- Development of ADCT-402 (loncastuximab tesirine), targeting CD19 for B-cell hematologic malignancies.
- ADCT-301 (camidanlumab tesirine), an anti-CD25 antibody-drug conjugate aimed at treating Hodgkin's lymphoma and solid tumors.
- Research on ADCT-601, an ADC targeting AXL-overexpressing solid and hematological tumors.
- Pipeline expansion into novel ADCs for oncology, focusing on unmet medical needs in both solid tumors and hematological malignancies.
- Collaborations with major pharmaceutical companies to leverage antibody-drug conjugate technology for cancer therapeutic development.
ADC Therapeutics SA executive team
- Ameet MallikCEO & Director
- Jose I. CarmonaChief Financial Officer
- Mohamed ZakiChief Medical Officer
- Lisa Michelle KalleboCorporate Controller & Chief Accounting Officer
- David S. EgeChief Technical Officer
- Nicole RileyHead of Investor Relations & Corporate Communications
- Peter J. GrahamSecretary and Chief Legal & Compliance Officer
- Kimberly PopeSenior VP & Chief People Officer
- Kristen Harrington-SmithChief Commercial Officer
- Marcy GrahamInvestor Relations Officer
Latest news about ADC Therapeutics SA
ADC Therapeutics completes LOTIS-7 enrollment in DLBCL study
United StatesADC Therapeutics completes LOTIS-7 enrollment in DLBCL study
United StatesADC Therapeutics restructures to focus on ZYNLONTA
United StatesADC Therapeutics reports $20M in revenue with critical clinical readouts imminent
United StatesADC Therapeutics secures cash runway to 2028 amid pivotal clinical momentum
United States
Key financials
Reported results for ADC Therapeutics SA, in USD.
- Market cap
- 196.6M
- Revenue (TTM)
- 79.6M
- P/E ratio
- —
- EPS (diluted, TTM)
- -0.6
- Dividend yield
- —
- Profit margin
- -121.8%
| Fiscal year end | Revenue | Operating income | Net income |
|---|---|---|---|
| 81.4M | -108.4M | -142.6M | |
| 70.8M | -130.7M | -157.8M | |
| 69.6M | -166M | -240.1M | |
| 209.9M | -123.3M | -157.1M |